Disclosed are compounds which are fluorescently labeled antagonists of the A3 adenosine receptor. Also disclosed are diagnostic of a patient for a possible treatment by an antagonist if the A3 adenosine receptor, involving the use of one or more of these compounds as diagnostic agents.
